ADAPTIVE BIOTECHNOLOGIES CORPORATION - CLONOSEQ HAS RECEIVED CLEARANCE FROM THE FOOD AND DRUG ADMINISTRATION FOR AN IN VITRO DIAGNOSTIC TEST SERVICE THAT DETECTS BLOOD CANCER IN PATIENTS.
Key Details
Description
CLONOSEQ HAS RECEIVED CLEARANCE FROM THE FOOD AND DRUG ADMINISTRATION FOR AN IN VITRO DIAGNOSTIC TEST SERVICE THAT DETECTS BLOOD CANCER IN PATIENTS.
Context & Analysis
On Nov 26, 2025, Department of Defense obligated $44,850 to ADAPTIVE BIOTECHNOLOGIES CORPORATION for clonoseq has received clearance from the food and drug administration for an in vitro diagnostic test service that detects blood cancer in patients.. The award is classified under NAICS 621511 — MEDICAL LABORATORIES and issued as a firm fixed price contract. Competition extent: competed under sap with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BETHESDA, MD. This award is one of several similar procurements from Department of Defense under NAICS 621511 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL REFERENCE LABORATORY TESTING SERVICES FOR FY25 NAVY LOCATION -BETHESDA
LABORATORY CORPORATION OF AMERICA
$6.8M
DPLAS FY26 1ST QUARTER TASK ORDER 1 OCT 2025- 31 DEC 2025
LABORATORY CORPORATION OF AMERICA
$5.1M
REFERENCE LABORATORY TESTING SERVICES FOR TRIPLER ARMY MEDICAL CENTER, HAWAII
LABORATORY CORPORATION OF AMERICA
$2.4M
NON-PERSONAL SERVICES CONTRACT TO PROVIDE CLINICAL REFERENCE LABORATORY TESTING SERVICES.
LABORATORY CORPORATION OF AMERICA
$2.3M
BLOOD DONOR SPECIMEN TESTING SERVICES FOR TRIPLER ARMY MEDICAL CENTER, HAWAII
BLOODWORKS
$1.7M
Stay Updated
Get notified about new opportunities matching your interests.